A protein has been identified that inhibits the growth of cancerous tumors and slows development of new blood vessels that allow cancers to spread. The protein is a variant of vascular endothelial growth factor A (VEGF-A), a substance known to promote cancer growth. The researchers named the variant VEGF-Ax. The protein cuts off the blood supply to tumors and inhibits tumor development in animal models. It could have major implications for the use of existing anti-VEGF therapies and the development of new drugs.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The findings were made by a team led by Paul Fox, PhD, of Cleveland Clinic’s Lerner Research Institute, and were published in Cell. “It is truly remarkable that a small change in a protein sequence leads not just to a protein with a different function, but one with a function completely opposite to the original,” says Dr. Fox. “In the context of cancer, the small extension changes a very ‘bad’ protein into a very ‘good’ one.”
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy